Search

Displaying results 2991 - 3000 of 10000 in total
  1. Pathway

    Cardiolipin Biosynthesis CL(18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)/18:1(9Z))

    smpdb.ca/view/SMP0220110
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition. It is essential for the optimal function of numerous enzymes that are involved in mitochondrial...

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  2. Drug

    Viagenpumatucel-L

    go.drugbank.com/drugs/DB16348
    Investigational

    Viagenpumatucel-L is under investigation in clinical trial NCT02117024 (A Phase 2 Study of Viagenpumatucel-l (HS-110) in Patients With Non-small Cell Lung Cancer).

    Synonyms: Gp96-igg1-fc fusion protein and hla-a1 expressing, irradiated ad-100 whole cell vaccine, Viagenpumatucel l
  3. Pathway

    Cardiolipin Biosynthesis CL(18:1(9Z)/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z))

    smpdb.ca/view/SMP0215035
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition. It is essential for the optimal function of numerous enzymes that are involved in mitochondrial...

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  4. Pathway

    Cardiolipin Biosynthesis CL(18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)/16:1(9Z)/18:4(6Z,9Z,12Z,15Z))

    smpdb.ca/view/SMP0220056
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition. It is essential for the optimal function of numerous enzymes that are involved in mitochondrial...

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  5. Drug

    Capivasertib

    go.drugbank.com/drugs/DB12218
    ApprovedInvestigational

    Therefore, targeting the PIK3/AKT pathway presents a promising approach for the treatment of breast cancer, leading to the development of capivasertib, a pan-AKT kinase inhibitor. … This approval is based on favorable results obtained from the CAPItello-291 trial, where the combination of capivasertib and [fulvestrant] reduced the risk of disease progression or death by 50% versus

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  6. Drug

    Clofedanol

    go.drugbank.com/drugs/DB04837
    ApprovedWithdrawn

    Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States.

    Mixtures: Vanacof G, Atuss Da
  7. Drug

    GC012F

    go.drugbank.com/drugs/DB22406
    Investigational

    GC012F is under investigation in clinical trial NCT06419166 (An Exploratory Clinical Study of GC012F Injection for Refractory gMG).

  8. Drug

    Foreskin keratinocyte (neonatal)

    go.drugbank.com/drugs/DB10772
    Approved

    To construct a "living" alternative, a dermal substitute based on collagen I gel was created with mesenchymal cells such as fibroblasts. … Keratinocytes are derived from neonatal foreskins and used to create a drug called _Apligraf_, a mixture of [DB10770] and keratinocytes.

  9. Pathway

    Cardiolipin Biosynthesis CL(18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)/20:3(11Z,14Z,17Z))

    smpdb.ca/view/SMP0220114
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition. It is essential for the optimal function of numerous enzymes that are involved in mitochondrial...

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  10. Drug

    VaxSyn

    go.drugbank.com/drugs/DB17827
    Investigational

    VaxSyn HIV-1 is a recombinant form of the HIV envelope protein gp 160 developed by MicroGeneSys and the National Institute of Allergy and Infectious Diseases (NIAID).